Ind-Swift Labs to sell API biz to IndiaRF for Rs 1,650 cr
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Advertisement
New Delhi, September 6
Drug firm Ind-Swift Laboratories on Wednesday said its Board has approved to sell active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) businesses to India Resurgence Fund (IndiaRF) for Rs 1,650 crore.
Advertisement
Chandigarh-based Ind-Swift has two manufacturing sites — in Punjab and Jammu, and a combined reactor capacity of 700 KL of active pharmaceutical ingredients (API) catering to both regulated and unregulated markets.
The company’s API business has a strong presence across the US, Japan, Korea, the European Union, Brazil and India.
India Resurgence Fund (IndiaRF), a leading India-focused investment platform promoted by Piramal Enterprises and Bain Capital, will acquire the business for a consideration of Rs 1,650 crore, the drug firm said.
Advertisement
“…IndiaRF will support and invest in the growth of the business,” Ind-Swift chairman and managing director NR Munjal said.
Advertisement
Advertisement